Auriclosene: Phase IIb data

A Phase IIb trial in patients with impetigo showed that a topical gel formulation of auriclosene missed the primary endpoint. Auriclosene was well tolerated. NovaBay and partner Galderma could not be reached for details, but said they are analyzing the data to determine next steps. Galderma has exclusive, worldwide rights to develop and commercialize NovaBay's Aganocide compounds, including auriclosene, for impetigo, acne and other dermatological indications (see BioCentury, March 30, 2009). ...